HEALTHCARE GLOB. ENT. LTD

Operates a network of cancer-care hospitals focused exclusively on oncology, following the divestiture of its Milann fertility business (sold to Inviga Healthcare Fund at a ₹63 crore enterprise valuation, expected to close in Q1 FY27). It earns revenue from in-patient and out-patient cancer treatment services across medical, surgical, radiation, nuclear medicine, PET-CT and bone marrow transplant (BMT), delivered through a distributed multi-cluster hospital network in India and a Kenya operation that grew 71% in FY26. In FY26 the company reported ₹2,545.41 crore in revenue (up 15% YoY) with adjusted EBITDA of ₹471.1 crore at 18.5% margin, and a net profit of ₹22.78 crore. The largest cost line is other operating expenses at 39.6% of revenue, followed by employee costs at 14.9% and depreciation at 9.6%, reflecting the asset-heavy nature of running comprehensive cancer centres. Growth is being funded by a completed ₹425 crore rights issue that cut net debt/EBITDA to 1.4x, with about ₹90–100 crore of capex directed to a brownfield expansion adding 200+ beds (Cuttack +75, Ranchi +30, Vizag +50, Bhavnagar 20+) over 24 months and a longer-term plan of roughly 1,000 bed additions by FY30 (400 greenfield, 600 brownfield). It is also scaling standalone Day-Care oncology centres from 5 to 15–20 over 24 months, and has launched a North Bangalore comprehensive oncology facility featuring MR-Linac technology, a first for Bangalore. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Oncology hospital services, Day-Care oncology centres, Kenya cancer-care operations. Asset-heavy, distributed hospital network operating exclusively in oncology after the Milann fertility divestiture

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)